Avalon Globocare Corp. · NASDAQ:ALBT
Avalon Globocare — Investor Presentation (May 2022)
24 slides from Avalon Globocare's investor presentation, May 2, 2022
Slide 1: Corporate Presentation May 2022
www.avalon - globocare.com Nasdaq: AVCO Corporate Presentation May 2022
Slide 2: Forward-Looking Statements
Certain statements contained in this presentation may constitute “forward - looking statements”, which provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact . Actual results may differ mate
Slide 3: Corporate Overview and Highlights
Mission: Avalon GloboCare Corp. (Nasdaq: AVCO) is a clinical - stage biotechnology company dedicated to develop and deliver innovative and transformative CellTech with multifunctional convergence in cellular technologies/therapeutics, precision diagnostics and intellectual property in the field of i
Slide 4: Corporate Overview and Highlights: Partnerships and IP
Corporate Overview and Highlights Leveraging platform through strategic partnering opportunities with academia and industries complementary to our R&D programs - Massachusetts Institute of technology - University of Pittsburgh Medical Center - Arbele Limited - HydroPeptide, LLC Strong Intellectual P
Slide 5: Senior Management, Board of Directors, Advisors
Nasdaq: AVCO 5 Senior Management, Board of Directors, Advisors Robert S. Langer, Sc.D. -- Massachusetts Institute of Technology; David H. Koch Institute Professor Yen - Michael Hsu, M.D., Ph.D.. -- University of Pittsburgh Medical Center, Chief of Cellular Therapy Peihua Peggy Lu, M.D -- Executive P
Slide 6: Key Differentiators
Ee Key Differentiators
Slide 7: Differentiator: Broad Spectrum of Immune Effectors
Differentiator: Broad Spectrum of Immune Effectors CAR - NK Cell Nasdaq: AVCO 7 Avalon - MIT
Slide 8: Differentiator: Seamless Integration of Vertical Segments
Differentiator: Seamless Integration of Vertical Segments Innovative Research, Novel Targets / Delivery, Strong IP Protection cGMP Bioprocessing & Bioproduction Capabitities, QC/QA, Accreditation (FACT, aaBB, CAP) Clinical Trial (IIT, IND) Infrastrructure, Seasoned Medical Team & CRA Upstream Midstr
Slide 9: CAR-T and FLASH-CAR Cell Therapy
CAR - T and FLASH - CAR TM Cell Therapy
Slide 10: AVA-001 (4-1BB anti-CD19 CAR-T)
AVA - 001 ( 4 - 1BB anti - CD19 CAR - T ) Avalon’s 3rd Generation CAR - T: AVA - 001, anti - CD19 CAR - T Co - developed with China Immunotech Co. Ltd. 4 - 1BB co - stimulatory signal driven Better cancer - killing efficacy Shorter bioproduction time ● Pre - clinical studies completed at end of Q2 2
Slide 11: Pilot First-in-Human Clinical Trial Demonstrates 90% CR Rate
Pilot First - in - Human Clinical Trial Demonstrates: Complete Remission (CR) Rate: 90% Minimal and well tolerated adverse side effects: no neurotoxicity or > Grade 1 cytokine release syndrome observed All patients achieved CR successfully proceeded to allogeneic BMT with curative intent AVA - 001 (
Slide 12: FLASH-CAR: A Multiplex, mRNA-CAR Platform
FLASH - CAR TM - - A Multiplex, mRNA - CAR Platform Nasdaq: AVCO 12
Slide 13: Lead Candidate: AVA-011 (Anti-CD19-CD22 CAR-T)
Lead Candidate: AVA - 011 (Anti - CD19 - CD22 CAR - T) • Autologous or universal CAR T targeting multiple tumor antigens • Proliferation inducer for in vivo expansion of CAR - T • Molecular safety switch • Rapid bio - production time (1 - 2 days) • Inducible vector for tumor site specific expression
Slide 14: Universal (off-the-shelf) CAR-NK Cell Therapy
Universal (“off - the - shelf”) CAR - NK Cell Therapy Tumor Cell Dr. Dongfang Liu Member of Avalon’s SCAB Nasdaq: AVCO 14
Slide 15: Avalon's Clinical Programs – Timeline and Milestones
Avalon’s Clinical Programs – Timeline and Milestones Nasdaq: AVCO 15
Slide 16: Strategic Partnerships
Ee Strategic Partnerships
Slide 17: Avalon Academic-Industry Partnership
Avalon Academic - Industry Partnership QTY Protein Design Code to Develop Decoy Cytokine & Chemokine Receptors to Combat “Cytokine Storm” and Cancer Metastasis (AVA - Trap Ρ ) Pls: Shuguang Zhang, Ph.D. Robert Langer, Sc.D. Process Development of Clinical - grade AVA - 011 (Flash - CAR Ρ ) and ACTEX
Slide 18: Avalon-MIT QTY Code Protein Design Platform
Avalon - MIT QTY Code Protein Design Platform QTY code - generated novel therapeutic targets for cancer immunotherapy and other clinical applications Nasdaq: AVCO 18
Slide 19: Avalon-MIT QTY Code Protein Design Platform
Avalon - MIT QTY Code Protein Design Platform Nasdaq: AVCO 19
Slide 20: Avalon ACTEX Platform
Avalon ACTEX TM Platform (Avalon Clinical - grade Tissue - specific Exosomes) Clinical - Grade Stem/Progenitor Cells Bio - production ACTEX Ρ (Avalon Clinical - Grade Tissue - Specific Exosomes) Accreditation/Standardization Infrastructures Nasdaq: AVCO 20
Slide 21: Strategic Partnership with HydroPeptide Q1 of 2023
Strategic Partnership with HydroPeptide Q1 of 2023 Nasdaq: AVCO 21
Slide 22: Broad and Deep IP Assets and Portfolio
Broad and deep IP assets and portfolio, with patent coverage across a number of key enabling technologies in CTx and CDx Avalon GloboCare Positions as Future Powerhouse in Cancer Immunotherapy and Cellular Medicine IP Intellectual Property ● Companion Dx ● Personalized Cellular Medicine ● Bio - info
Slide 23: Corporate Council, American Society of Transplantation and Cellular Therapy (ASTCT)
Corporate Council, American Society of Transplantation and Cellular Therapy (ASTCT) Nasdaq: AVCO 23
Slide 24: Contact
www.avalon - globocare.com Nasdaq: AVCO Contact: Corporate Address: Avalon Executive Center 4400 Route 9 South, Suite 3100 Freehold, New Jersey 07728, USA Phone: +1 – 732 - 780 - 4400 Fax: +1 – 732 - 780 - 5600 Website: www.avalon - globocare.com IR Email: avco@crescendo - ir.com Thank You